Roche has told a scientific meeting in San Diego that its candidate antibody for patients with severe uncontrolled asthma and high levels of periostin has shown promising results in two Phase 2b studies. The antibody, lebrikizumab, targets IL-13. ---Subscribe to MedNous to access this article--- Clinical Research Company News
